Belinostat: First Global Approval

Overview

Journal Drugs

Specialty Pharmacology

Date 2014 Aug 20

PMID 25134672

Citations 69

Authors

Raewyn M Poole

Affiliations

Soon will be listed here.

Abstract

Belinostat [Beleodaq(®) (US)], a small-molecule hydroxamate-type inhibitor of class I, II and IV histone deacetylase (HDAC) enzymes, has been developed by TopoTarget and Spectrum Pharmaceuticals for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Belinostat has received its first global approval as monotherapy for this indication in the US, under the Food and Drug Administration's accelerated approval program. This article summarizes the milestones in the development of belinostat leading to this first approval for the treatment of PTCL.

Citing Articles

Epigenetic marvels: exploring the landscape of colorectal cancer treatment through cutting-edge epigenetic-based drug strategies.

Tahghighi A, Seyedhashemi E, Mohammadi J, Moradi A, Esmaeili A, Pornour M Clin Epigenetics. 2025; 17(1):34.

PMID: 39987205 PMC: 11847397. DOI: 10.1186/s13148-025-01844-w.

Histone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory Diseases.

Theodoropoulou M, Mantzourani C, Kokotos G Biomolecules. 2025; 14(12.

PMID: 39766311 PMC: 11674560. DOI: 10.3390/biom14121605.

Epigenetics-targeted drugs: current paradigms and future challenges.

Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S Signal Transduct Target Ther. 2024; 9(1):332.

PMID: 39592582 PMC: 11627502. DOI: 10.1038/s41392-024-02039-0.

Discovery of a Novel and Potent Dual-Targeting Inhibitor of ATM and HDAC2 Through Structure-Based Virtual Screening for the Treatment of Testicular Cancer.

Ruan Y, Guan L, Wang Y, Geng Y, Wang X, Niu M Drug Des Devel Ther. 2024; 18:5283-5297.

PMID: 39583632 PMC: 11585990. DOI: 10.2147/DDDT.S479113.

Unveiling the role of histone deacetylases in neurological diseases: focus on epilepsy.

Cao D, Zhou X, Guo Q, Xiang M, Bao M, He B Biomark Res. 2024; 12(1):142.

PMID: 39563472 PMC: 11575089. DOI: 10.1186/s40364-024-00687-6.

References

Narlikar G, Fan H, Kingston R . Cooperation between complexes that regulate chromatin structure and transcription. Cell. 2002; 108(4):475-87. DOI: 10.1016/s0092-8674(02)00654-2. View

Ma X, Ezzeldin H, Diasio R . Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs. 2009; 69(14):1911-34. DOI: 10.2165/11315680-000000000-00000. View

Escalon M, Liu N, Yang Y, Hess M, Walker P, Smith T . Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer. 2005; 103(10):2091-8. DOI: 10.1002/cncr.20999. View

Dai Y, Chen S, Wang L, Pei X, Kramer L, Dent P . Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim. Br J Haematol. 2011; 153(2):222-35. PMC: 3358826. DOI: 10.1111/j.1365-2141.2011.08591.x. View

Warren K, McCully C, Dvinge H, Tjornelund J, Sehested M, Lichenstein H . Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates. Cancer Chemother Pharmacol. 2007; 62(3):433-7. DOI: 10.1007/s00280-007-0622-5. View

Chowdhury S, Howell G, Teggart C, Chowdhury A, Person J, Bowers D . Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death. J Biol Chem. 2011; 286(35):30937-30948. PMC: 3162453. DOI: 10.1074/jbc.M110.212035. View

Steele N, Plumb J, Vidal L, Tjornelund J, Knoblauch P, Buhl-Jensen P . Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemother Pharmacol. 2010; 67(6):1273-9. DOI: 10.1007/s00280-010-1419-5. View

Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn L . Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013; 31(16):1970-6. DOI: 10.1200/JCO.2012.44.7524. View

Spratlin J, Pitts T, Kulikowski G, Morelli M, Tentler J, Serkova N . Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. Anticancer Res. 2011; 31(4):1093-103. PMC: 3866806. View

10.

Marquard L, Petersen K, Persson M, Hoff K, Jensen P, Sehested M . Monitoring the effect of belinostat in solid tumors by H4 acetylation. APMIS. 2008; 116(5):382-92. PMC: 2774150. DOI: 10.1111/j.1600-0463.2008.00957.x. View

11.

Tumber A, Collins L, Petersen K, Thougaard A, Christiansen S, Dejligbjerg M . The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol. 2006; 60(2):275-83. DOI: 10.1007/s00280-006-0374-7. View

12.

Qian X, Ara G, Mills E, LaRochelle W, Lichenstein H, Jeffers M . Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int J Cancer. 2007; 122(6):1400-10. DOI: 10.1002/ijc.23243. View

13.

Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C . Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2007; 6(1):37-50. DOI: 10.1158/1535-7163.MCT-05-0285. View

14.

Candelaria M, Gallardo-Rincon D, Arce C, Cetina L, Aguilar-Ponce J, Arrieta O . A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol. 2007; 18(9):1529-38. DOI: 10.1093/annonc/mdm204. View

15.

Vose J, Armitage J, Weisenburger D . International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26(25):4124-30. DOI: 10.1200/JCO.2008.16.4558. View

16.

Qian X, LaRochelle W, Ara G, Wu F, Petersen K, Thougaard A . Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther. 2006; 5(8):2086-95. DOI: 10.1158/1535-7163.MCT-06-0111. View

17.

Dai Y, Chen S, Kramer L, Funk V, Dent P, Grant S . Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin Cancer Res. 2008; 14(2):549-58. DOI: 10.1158/1078-0432.CCR-07-1934. View

18.

Reimer P, Chawla S . Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma. J Hematol Oncol. 2013; 6:69. PMC: 3846498. DOI: 10.1186/1756-8722-6-69. View

19.

MacKay H, Hirte H, Colgan T, Covens A, MacAlpine K, Grenci P . Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer. 2010; 46(9):1573-9. PMC: 3244274. DOI: 10.1016/j.ejca.2010.02.047. View

20.

Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan V, OConnor O . Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res. 2010; 16(2):554-65. DOI: 10.1158/1078-0432.CCR-09-1937. View